Skip to content
Boca Raton City Online – Lifestyle
Author:
GT Medical Technologies
GT Medical Technologies Completes Oversubscribed $100 Million Series E Equity Financing to Advance Commercial Treatment for Patients with Operable Brain Tumors
June 9, 2026
ROADS Phase 3 Clinical Trial Data Presented at ASCO26 Show GammaTile® Provides Superior Tumor Control Leading to Patients Living Longer Without Recurrence Compared to Standard of Care in Newly Diagnosed Operable Brain Metastases
May 30, 2026
Prospective Multicenter Registry Study Reports High Local Tumor Control Following Resection with GammaTile® in Newly Diagnosed Brain Metastases
March 8, 2026